JP2023512823A5 - - Google Patents

Info

Publication number
JP2023512823A5
JP2023512823A5 JP2022548109A JP2022548109A JP2023512823A5 JP 2023512823 A5 JP2023512823 A5 JP 2023512823A5 JP 2022548109 A JP2022548109 A JP 2022548109A JP 2022548109 A JP2022548109 A JP 2022548109A JP 2023512823 A5 JP2023512823 A5 JP 2023512823A5
Authority
JP
Japan
Prior art keywords
alkyl
group
alkoxy
hydrogen
hydrocarbyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022548109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512823A (ja
JP7678595B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016848 external-priority patent/WO2021158936A1/en
Publication of JP2023512823A publication Critical patent/JP2023512823A/ja
Publication of JP2023512823A5 publication Critical patent/JP2023512823A5/ja
Application granted granted Critical
Publication of JP7678595B2 publication Critical patent/JP7678595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022548109A 2020-02-05 2021-02-05 ピロロ[2,3‐b]ピリジン‐3‐カルボキサミド組成物及び聴力損失を改善するための方法 Active JP7678595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970425P 2020-02-05 2020-02-05
US62/970,425 2020-02-05
PCT/US2021/016848 WO2021158936A1 (en) 2020-02-05 2021-02-05 Pyrrolo [2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss

Publications (3)

Publication Number Publication Date
JP2023512823A JP2023512823A (ja) 2023-03-29
JP2023512823A5 true JP2023512823A5 (cg-RX-API-DMAC7.html) 2025-03-21
JP7678595B2 JP7678595B2 (ja) 2025-05-16

Family

ID=77199407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548109A Active JP7678595B2 (ja) 2020-02-05 2021-02-05 ピロロ[2,3‐b]ピリジン‐3‐カルボキサミド組成物及び聴力損失を改善するための方法

Country Status (9)

Country Link
US (1) US12617785B2 (cg-RX-API-DMAC7.html)
EP (1) EP4100008B1 (cg-RX-API-DMAC7.html)
JP (1) JP7678595B2 (cg-RX-API-DMAC7.html)
CN (1) CN115515579B (cg-RX-API-DMAC7.html)
AU (1) AU2021215925B2 (cg-RX-API-DMAC7.html)
CA (1) CA3170121A1 (cg-RX-API-DMAC7.html)
ES (1) ES3025983T3 (cg-RX-API-DMAC7.html)
MX (1) MX428671B (cg-RX-API-DMAC7.html)
WO (1) WO2021158936A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515579B (zh) 2020-02-05 2025-09-30 洛克菲勒大学 吡咯并[2,3-b]吡啶-3-甲酰胺组合物和改善听力损失的方法
EP4380562A4 (en) * 2021-08-02 2025-05-21 The Rockefeller University PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELL PROLIFERATION
EP4687896A1 (en) * 2023-04-04 2026-02-11 Children's Hospital Los Angeles Lats kinase inhibitor to treat retinal degeneration
WO2026010871A1 (en) * 2024-07-01 2026-01-08 Hudspeth A James ((pyrrolopyridine-3-carbonyl) imino)-2,3-dihydrothiazol-4-yl) methyl phosphates for activating yap
KR20260029093A (ko) * 2024-08-23 2026-03-04 한국화학연구원 카이네이즈 억제제
WO2026043170A1 (ko) * 2024-08-23 2026-02-26 한국화학연구원 카이네이즈 억제제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
FR2888848B1 (fr) * 2005-07-22 2007-09-28 Sanofi Aventis Sa Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
WO2007067537A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
KR101591153B1 (ko) 2010-12-20 2016-02-02 그렌마크 파머수티칼스 에스. 아. Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
JOP20190257A1 (ar) * 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
CN115515579B (zh) 2020-02-05 2025-09-30 洛克菲勒大学 吡咯并[2,3-b]吡啶-3-甲酰胺组合物和改善听力损失的方法

Similar Documents

Publication Publication Date Title
ES2810852T3 (es) Compuestos y composiciones para inhibir la actividad de shp2
US20240374595A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
US12006328B2 (en) Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
JP2021534124A5 (cg-RX-API-DMAC7.html)
AU2013262320B2 (en) High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
JP5822840B2 (ja) 眼疾患処置薬
CA2571347A1 (en) Piperazine derivatives for the treatment of female sexual disorders
RU2557982C2 (ru) Композиции и способы ингибирования пути jak
JP2005536475A5 (cg-RX-API-DMAC7.html)
JP2007519649A5 (cg-RX-API-DMAC7.html)
CN107660202B (zh) 水溶性前药
BR112021006033A2 (pt) Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
JP2023512828A (ja) クロマカリムプロドラッグ療法のための改善された方法及び組成物
RU2012147511A (ru) Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза
JP2004525183A5 (cg-RX-API-DMAC7.html)
PT1948176E (pt) Diaril ureias para tratar a hipertensão pulmonar
TW202114991A (zh) 離胺醯氧化酶之二氟鹵烯丙胺碸衍生物抑制劑、製備方法、及其用途
JP2008543781A5 (cg-RX-API-DMAC7.html)
KR102792934B1 (ko) 세페타프로스트와 Rho 키나아제 저해제의 조합 의약
JP4933897B2 (ja) 眼内移行性促進水性点眼剤
JP2022519274A5 (cg-RX-API-DMAC7.html)
JP2009514910A (ja) 肺高血圧を処置するためのジアリールウレア
US20230046317A1 (en) Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer
JP2023550902A5 (cg-RX-API-DMAC7.html)